Search results
Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further...
FOX 59 Indianapolis· 20 hours agoIn the ALIGN study, atrasentan, in addition to supportive care with a renin-angiotensin system (RAS)...
C3 Glomerulopathy: Not Just for Nephrologists
Medscape· 6 days agoWhat is C3 glomerulopathy? This is an inflammatory disease state of the filters of the kidney, the glomeruli. It has to be distinguished from other forms...
Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing...
WJET - WFXP Erie· 21 hours agoNovartis today presented results from the 6-month, double-blind period of the Phase III APPEAR-C3G...
FDA approves belimumab autoinjector for pediatric systemic lupus erythematosus
Medical Xpress· 3 days agoThe U.S. Food and Drug Administration has approved GlaxoSmithKline's 200-mg subcutaneous route of...
HI-Bio Announces Positive Results from Phase 2 Study of Felzartamab for Late Antibody-Mediated...
KOLR - KSFX Ozarks· 20 hours ago82% (n=9/11) of patients on felzartamab experienced resolution of antibody-mediated rejection per Banff criteria on biopsy at 24 weeks versus 20% (n=2/10) who received placebo, and patients ...
GRI Bio reports promising preclinical SLE treatment data By Investing.com
Investing.com· 5 days agoPreclinical studies indicate that oral administration of GRI-0803 significantly improved overall...
All over the body: Here are the key clinical trials from Bay Area firms - San Francisco Business...
The Business Journals· 1 day agoSince the turn of the millennium, Bay Area organizations and researchers have launched more than 300...
Vera Therapeutics Presents 72-week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b...
Benzinga· 17 hours agoVera Therapeutics, Inc. VERA, a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases ...
HI-Bio Presents Positive Interim Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy...
WKRN Nashville· 2 days agoPatients receiving nine-dose regimen over five months experienced deep and durable reduction in proteinuria, reaching up to ~50% mean reduction in UPCR at end of study at month 24 and over 18 ...
Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human...
Morningstar· 4 days agoBiogen Inc. (Nasdaq: BIIB) and Human Immunology Biosciences (HI-Bio™), a privately-held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated ...